Optimization of immunoglobulin substitution therapy by a stochastic immune response model

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Figge, Marc Thilo ^a  

^a FRANKFURT INSTITUTE FOR ADVANCED STUDIES   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G;

ADAPTIVE IMMUNITY; ARTICLE; COMPUTER SIMULATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOMODULATION; INFECTION; MATHEMATICAL ANALYSIS; OPPORTUNISTIC INFECTION; PERSISTENT INFECTION; STOCHASTIC MODEL; SUBSTITUTION THERAPY; BIOLOGICAL MODEL; COMMUNICABLE DISEASE; HUMAN; IMMUNOLOGY; MICROBIOLOGY; PASSIVE IMMUNIZATION; STATISTICS; TIME;

COMMUNICABLE DISEASES; COMPUTER SIMULATION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MODELS, IMMUNOLOGICAL; STOCHASTIC PROCESSES; TIME FACTORS;

EID: 66549109067     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005685     Document Type: Article

References (42)

1. Mix E, Goertsches R, Zettl U (2006) Immunoglobulins - Basic considerations. J Neurol 253: V/9-V/17.
2. Janeway CA, Travers P, Walport M, Slomchik MJ (2005) Immunobiology - The immune system in health and disease. New York and London: Garland Science Publishing.
3. MacLennan ICM (1994) Germinal Centers. Annu Rev Immunol 12: 117-139.
4. Manser T (2004) Textbook Germinal Centers? J Immunol 172: 3369-3375.
5. Meyer-Hermann M, Figge MT, Toellner KM (2009) Germinal centres seen through the mathematical eye: B cell models on the catwalk. Trends Immunol 30: 157-164.
6. Figge MT, Garin A, Gunzer M, Kosco-Vilbois M, Toellner KM, et al. (2008) Deriving a germinal center lymphocyte migration model from two-photon data. J Exp Med 205: 3019-3029.
7. Marodi L, Notarangelo L (2007) Immunologlical and genetic bases of new primary immunodeficiencies. Nature Immunol 7: 851-861.
8. Bruton OC (1952) Agammaglobulinemia. Pediatrics 9: 722-728.
9. Buckley RH (1998) Commentary: Agammaglobulinemia, by Col. Ogden C. Bruton. Pediatrics 102: 213-215.
10. Gaspar HB, Conley ME (2000) Early B cell defects. Clin Exp Immunol 119: 383-389.
11. Vetrie D, Voechovsky I, Sideras P, Holland J, Davies A, et al. (1993) The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361: 226-233.
12. Tsukadab S, Saffranb DC, Rawlingsb DJ, Parolinih O, Allend RC, et al. (1993) Deficient expression of a B-cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72: 279-290.
13. Orange JS, Hossny EM, Weiler CR, Ballow M, Berger M, et al. (2006) Use of intravenous immunoglobulin in human disease: A review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 117: S525-S553.
14. Stangel M, Pul R (2006) Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 253: V/18-V/24.
15. Berger M (2008) Principles of and Advances in Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Immunol Allergy Clin N Am 28: 413-437.
16. Eibl MM (2008) History of Immunoglobulin Replacement. Immunol Allergy Clin N Am 28: 737-764.
17. Kirmse J (2006) Subcutaneous Administration of Immunoglobulin. J Infusion Nurs 29: 15-20.
18. Gardulf A (2007) Immunoglobulin Treatment for Primary Antibody Deficiencies: Advantages of the Subcutaneous Route. BioDrugs 21: 105-116.
19. Moore ML, Quinn JM (2008) Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol 101: 114-121.
20. Milgrom H (1998) Shortage of intravenous immunoglobulin. Ann Allergy Asthma Immunol 81: 97-100.
21. Bayry J, Kazatchkine MD, Kaveri SV (2007) Shortage of human intravenous immunoglobulin: reasons and possible solutions. Nature Clin Pract Neurol 3: 120-121.
22. MacGregor AG, Wayne EJ (1951) Fluorescein test of circulation time in peripheral vascular disease. Br Heart J 13: 80-88.
23. Fujikawa H, Kai A, Morozumi S (2004) Improvement of New Logistic Model for Bacterial Growth. J Food Hyg Soc Japan 45: 250-254.
24. Van Impe JF, Poschet F, Geeraerd AH, Vereecken KM (2005) Towards a novel class of predictive microbial growth models. Int J Food Microbiology 100: 97-105.
25. Peleg M, Corradini MG, Normand MD (2007) The logistic (Verhulst) model for sigmoid microbial growth curves revisited. Food Res Int 40: 808-818.
26. Perelson AS, Oster GF (1979) Theoretical studies of clonal selection: Minimal antibody repertoire size and reliability of self-non-self discrimination. J Theor Biol 81: 645-670.
27. Press WH, Teukolsky SA, Vetterling WT, Flannery BP (2007) Numerical Recipes: The Art of Scientific Computing. Cambridge: Cambridge University Press.
28. Risken H (1996) The Fokker-Planck Equation - Methods of Solutions and Applications. Berlin: Springer.
29. American Society of Health-System Pharmacists (2007) www.ashp.org.
30. Canadian Blood Services (2007) www.blood.ca.
31. Kazatchkine MD, Kaveri SV (2001) Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 345: 747-755.
32. Tha-In T, Bayry J, Metselaar H, Kaveri S, Kwekkeboom J (2008) Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 29: 608-615.
33. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, V VD, et al. (2003) Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101: 758-765.
34. Hurez V, Kaveri S, Mouhoub A, Dietrich G, Mani J, et al. (1994) Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. Ther Immunol 1: 269-277.
35. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, et al. (1996) Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 97: 865-869.
36. Aukrust P, Froland S, Liabakk N, Müller F, Nordoy I, et al. (1994) Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 84: 2136-2143.
37. Andersson J, Skansn-Saphir U, Sparrelid E, Andersson U (1996) Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages. Exp Immunol 104: 10-20.
38. Jungi T, Brcic M, Kuhnert P, Spycher M, Li F, et al. (1990) Effect of IgG for intravenous use on Fc receptor-mediated phagocytosis by human monocytes. Clin Exp Immunol 82: 163-169.
39. Stangel M, Joly E, Scolding N, Compston D (2000) Normal polyclonal immunoglobulins (IVIg) inhibit microglial phagocytosis in vitro. J Neuroimmunol 106: 137-144.
40. Takai T (2005) Fc Receptors and Their Role in Immune Regulation and Autoimmunity. J Clin Immunol 25: 1-18.
41. Prasad N, Papoff G, Zeuner A, Bonnin E, Kazatchkine M, et al. (1998) Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: A novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 161: 3781-3790.
42. Figge MT (2002) Statistical model for receptor-ligand binding thermodynamics. Phys Rev E 66: 061901.